Solid Implants

InnoCore's injectable biodegradable solid implants find applications as drug delivery depots in various chronic disease areas, including ophthalmology, oncology and CNS.

They can be used for local as well as for systemic drug delivery of small molecules and peptides for up to six months. InnoCore has the disposal of advanced (micro)extrusion technologies allowing effective implant formulation development of the customers active compound with bioresorbable polymers.

The ability to extrude the SynBiosys bioresorbable polymers at relatively low temperatures enables InnoCore to add a valuable depot formulation technology to its drug delivery portfolio. These low temperatures are a key pre-requisite to maintaining drug integrity and preventing the formation of degradation products, especially when biotherapeutics are involved.

Implants with high drug loading and well-defined release and biodegradation kinetics are designed by using the most appropriate SynBiosys configurations in the blending- and extrusion process to create novel drug delivery products for our customers.

The use of injectable solid implants based on proprietary SynBiosys bioresorbable polymers opens opportunities for optimised product performance and life cycle management of generic drugs and will therefore add significant value. Newly developed pharmaceutical actives formulated into a solid injectable controlled release mini-rod can benefit from the versatile SynBiosys chemistry as well as through optimised control over release kinetics and minimisation of side effects.